JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

CLINICAL GASTROENTEROLOGY

Category: № 12 (148) 2017 y
    1. Omsk State Medical Information-Analytical Centre (Omsk, Russian Federation)
    2. Omsk State Medical University (Omsk, Russian Federation)
    3. Omsk State Medical Diagnostic Center (Omsk, Russian Federation)

    Keywords: stomach, Helicobacter pylori, strains of non-steroidal anti-inflammatory drugs (NSAIDs)

    Abstract: The study included 34 patients (15 men and 19 women, average age 56,7±1,46). The test was divided into three groups, with the additional inclusion criterion of I and II groups was the use of a patient NSAIDs for at least 30 calendar days prior to the survey. A study of strains of Helicobacter pylori (HP) in gastric mucosa of adult patients receiving non-steroidal anti-inflamatory drugs (NSAIDs). HP genotyping was performed by PCR. In the General structure of the studied biopsy specimens was often identified genotype vac A s1/m1, cag A+; iceA1 (7 cases out of 34 (of 20.58 %), p<0.05). The distribution of genotypes in the clinical groups were quite heterogeneous, the Results of the conducted studies, despite some heterogeneity, indicate the presence of statistically significant differences depending on the presence of erosive-ulcerative changes and factors of NSAIDs.

      1. Telford J.L., Covacci A., Rappuoli R., Ghiara P. Immunobiology of Helicobacter pylori infection. Current Opinion Immunology. 1997;9(4):498-503.
      2. Walker M.M., Crabtree J.E. Helicobacter pylori infection and the pathogenesis of duodenal ulceration. Annals of the New York Academy Sciences. 1998;859:96-111.
      3. Ширинская Н.В., Ахмедов В.А. NPVP-gastropatiya i Helicobacter pylori: bol'she voprosov, chem otvetov. Eksperimental’naya i Klinicheskaya Gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2010;9:116-120.
      4. Huang J.Q., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14-22.
      5. Hawkey C.J., Tulassay Z., Szczepanski L., et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet. 1998;352:1016-1021.
      6. Cover T.L., Blaser M.J. Purification and characterization of the vacuolating toxin from Helicobacter pylori. Journal of Biological Chemistry. 1992;267(15):10570-10575.
      7. Odenbreit S., Puls J., Sedlmaier B., Gerland E., Fischer W., Haas R. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science. 2000;287(5457):1497-1500.
      8. Cover T.L. The vacuolating cytotoxin of Helicobacter pylori. Molecular Microbiology. 1996;20(2):241-246.
      9. Suzuki R., Shiota S., Yamaoka Y. Molecular epidemiology, population genetics, and pathogenic role of Helicobacter pylori. Infection Genetics and Evolution. 2012;12(2):203-213.
      10. Gu Q., Xia H.H., Wang W.H., Wang J.D., Wong W.M., Chan A. O. O., Yuen M. F., Lam S. K., Cheung H. K.-L., Liu X. G., Wong B. C.-Y. Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin. Alimentary Pharmacology and Therapeutics. 2004;20(6):675-681.
      11. Wang W.H., Wong W.M., Dailidiene D., Berg D.E., Gu Q., Lai K.C., Lam S.K., Wong B.C.Y. Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut. 2003;52(4):490-495.
      12. Wang W.H., Hu F.L., Wong B.C.Y, Lam S.K. Inhibitory effects of aspirin and indometacin on the growth of Helicobacter pylori in vitro. Chinese Journal of Digestive Diseases. 2002;3(4):172-177.
      13. Shirin H., Moss S.F., Kancherla S., Kancherla K., Holt P.R, Weinstein I.B. Sordillo E.M. Non-steroidal anti-inflammatory drugs have bacteriostatic and bactericidal activity against Helicobacter pylori. Journal of Gastroenterology and Hepatology. 2006;21(9):1388-1393.
      14. Ma H.X., Wang W.H., Hu F.L., et al. Effect of aspirin and celecoxib on Helicobacter pylori in vitro. Shijie Huaren Xiaohua Zazhi. 2006;14:2747-2752.
      15. Barkin J. The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs. The American Journal of Medicine. 1998;105(5):22S-27S.
      16. Hudson N., Balsitis M., Filipowicz F., Hawkey C.J. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut. 1993,34(6):748-751.
      17. Proença-Modena J.L., Acrani G.O., Brocchi M. Helicobacter pylori: phenotypes, genotypes and virulence genes. Future Microbiology. 2009;4(2):223-240.


    Full text is published :
    Shirinskaya N.V., Pomorgailo E.G., Akhmedov V.A., Vas'kina T.V., Kirichenko N.P. GENOTYPE HELICOBACTER PYLORI AT NSAIDS TAKING PATIENTS. Experimental and Clinical Gastroenterology Journal. 2017;148(12):9-13.
    Read & Download full text

    1. Federal State Budgetary and Educational Institution of Higher Education of the Russian Federation “Dagestan State Medical University” (Makhachkala, The Republic of Dagestan, Russian Federation)

    Keywords: chronic gastritis, peptic ulcer of duodenum, cytokines

    Abstract:: The aim of research was to evaluate the effectiveness of the effect of eradication therapy on the cytokine status of gastric juice in patients with chronic non-atrophic gastritis (HNG) and duodenal ulcer (duodenal ulcer) associated with Helicobacter pylori.
    Materials and methods. Clinical observations and laboratory-instrumental studies were performed in 95 patients aged 20 to 55 years with HNG and duodenal ulcer with determination of cytokine content of IL-1β, IL-6 and TNF-α in the fasting portion of gastric juice.
    Results. The most pronounced decrease in the content of proinflammatory cytokines in gastric juice on the background of treatment was found in patients of the 1st group who received combined therapy according to the scheme omeprazole ++ clarithromycin + amoxicillin. Analysis of the content of proinflammatory cytokines (IL-1β, IL-6 and TNF-α) in gastric juice in patients with acute exacerbation showed that their concentration in all 8 patients after the course of therapy exceeded the norm (P <0.05) and was IL–1β — 30,30 + 1,15 pg / l, IL-6–10,4 + 0,83 pg / l and TNF-α — 32,5 + 1,13 pg / l. At the same time, the level of proinflammatory cytokines in gastric juice correlated with the degree of dissemination of H. pylori in the mucosa of the gastroduodenal zone.
    Сonclusion. Helicobacter pylori infection in inflammation and ulceration in the mucous membrane of the stomach and duodenum, possibly in addition to other mechanisms, affects the activation of proinflammatory cytokines (IL-1beta, IL-6, TNF-alpha) in gastric juice. Incomplete eradication of H. рylori after treatment during clinical endoscopic remission in patients with duodenal ulcer in the vast majority of cases is accompanied by the preservation of an increased level of pro-inflammatory cytokines in gastric juice, which may be one of the reasons for the relapse of the disease.

      1. Ageeva E.S. Assotsiatsiya polimorfizmov genov G-174 CIL6 i T-251A IL8 s yazvennoi bolezn'yu u Khakasov. Immunologija. 2010;31(3):131-133.< /li>
      2. Maev I.V. Sovremennye standarty lechenija kislotozavisimyh zabolevanij, associirovannyh s Helicobacter pylori. Materialy konsensusa «Maastriht-3». Consilium Medicum. Pril.: Gastroenterologiya. 2006;1 pp. 3–8.
      3. Maev I.V. Vazhnye prakticheskie rezul'taty i sovremennye tendentsii v izuchenii zabolevanii zheludka i dvenadtsatiperstnoi kishki. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology 2012;4:17-26.
      4. Oradova A.Sh., Ustenova G.O., Stabaeva G.S. Metody issledovaniya tsitokinov [Methods of cytokine research]. Medicine. 2014;10:84-87
      5. Osadchuk M.M. Khelikobakterioz. Aktual'nye i nereshennye problemy patogeneza i lecheniya. Prakticheskaya meditsina. 2012;56(1):16-21.
      6. Stepchenko A.A. Uroven' pro- i protivovospalitel'nykh tsitokinov, fenotip okislitel'nogo metabolizma u bol'nykh yazvennoi bolezn'yu, assotsiirovannoi s razlichnymi shtammami Helicobacter pylori. Kurskii nauchno-prakticheskii vestnik «Chelovek i ego zdorov'e». 2010;3:134-139.
      7. Bayraktaroglu T. Serum levels of tumor necrosis factor-a, interleukin-6 and interleukin-8 are not increased in dyspeptic patients with Helicobacter pylori – associated gastritis. Mediators of inflammation. 2004;13(1):25-28.
      8. Kasifoglu N. IL8 serum levels in patients with Helicobacter pylori infection and relation between serological marcers. African journal of microbiology research. 2009;3(11):822-825.


    Full text is published : Esedov E.M., Akbieva D.S. EFFECTIVENESS OF THE EFFECTS OF ERADICATION THERAPY ON THE CONTENT OF PROINFLAMMATORY CYTOKINES IN GASTRIC JUICE IN PATIENTS WITH CHRONIC GASTRODUODENAL DISEASES ASSOCIATED WITH. Experimental and Clinical Gastroenterology Journal. 2017;148(12):14-19
    Read & Download full text

    1. North-Western State Medical University n. a. I.I. Mechnikov (Saint Petersburg, Russian Federation)
    2. SM–clinic (Saint Petersburg, Russian Federation)

    Keywords: Helicobacter pylori, epidemiology of H. pylori, H. pylori and physicians, 13С-urea breath test, anti-helicobacter therapy, eradication

    Abstract: The article presents the results of the first observation epidemiological study on H. pylori infection among physicians (therapists). 1154 doctors from 14 different regions of Russian Federation were examined by using 13С-urea breath test. High prevalence of H. pylori (59 %) among doctors was found. The prevalence of H. pylori among doctors according to the different regions and age groups of doctors was estimated. The prevalence of H. pylori in the group of doctors under the age of 30 y. o. was 45,2 %, in the group of 51–60 y. o. — 65,2 %, respectively. Treatment for eradication H. pylori among 619 of H. pylori-positive doctors was received only 114 (18.9 %) doctors and therapy achieved elimination of the infection in 69.2 % cases.

      1. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.
      2. IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8); pp. 174–180.
      3. Hooi J.K., Lai W.Y., Ng W.K., Suen M.M.Y., Underwood F.E., Tanyingoh D., Malfertheiner P., Graham D.Y., Wong V.W.S., Wu J.C.Y., Chan F.K.L., Sung J.J.Y., Kaplan G.G., Ng S.C. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420–429.
      4. Abdulkhakov R.A., Abdulkhakov S.R. Epidemiologiya Helicobacter pylori. Prakticheskaya meditsina. 2006;18(4):2–3.
      5. Roman L., Lukyanchuk R., Sablin O. Prevalence of H. pylori Infection and Atrophic Gastritis in a Population-based Screening with Serum Biomarker Panel (GastroPanel®) in St. Petersburg. Anticancer Res. 2016;36(8):4129–4138.
      6. Rakhmanin Yu.A., Zykova I. E., Fedichkina T. P. i dr. Izuchenie territorial'nogo raspredeleniya infitsirovannosti Helicobacter pylori trudosposobnogo naseleniya g. Moskvy v khode dispanserizatsii proizvodstvennykh kontingentov. Gigiena i sanitariya. 2013;92(5):79–82.
      7. Kurilovich S.A., Reshetnikov O.V. Epidemiologicheskie issledovaniya v gastroenterologii: mnogoletnii sibirskii opyt izucheniya Helicobacter pylorii assotsiirovannykh zabolevanii. Eksperimental'naya i klinicheskaya gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2015;3:4–10.
      8. Tsukanov V.V., Amel'chugova O.S., Butorin N.N. et al. Sovremennye aspekty eradikatsii Helicobacter pylori. Ter. arkhiv. 2013;2:73–5.
      9. Zakharova N.V., Simanenkov V. I., Bakulin I.G., Sablin O.A., Il'chishina T.A., Zakharov D.V. Rasprostranennost' khelikobakternoi infektsii u patsientov gastroenterologicheskogo profilya v Sankt-Peterburge. Farmateka. 2016;5(16):33–39.
      10. Brown L.M. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol. Rev. 2000;22:2:283–97.
      11. Mastromarino P., Conti C., Donato K., Strappini P.M., Cattaruzza M.S., Orsi G.B. Does hospital work constitute a risk factor for Helicobacter pylori infection? The Journal Hospital Infecion. 2005;60(3):261–268.
      12. Peters C., Schablon A.,1 Harling M.,1 Claudia Wohlert C., J.T., Nienhaus A. The occupational risk of Helicobacter pylori infection among gastroenterologists and their assistants. BMC Infect Dis. 2011;31(11):154.
      13. Mastromarino P. et al. Helicobacter pylori infection among healthcare workers: further investigation is needed. J Hosp Infect. 2007;66(3):297–298.
      14. Kim H.Y., Kim N., Kim S. M. et al. Seroprevalence of Helicobacter pylori infection in Korean Health Personnel. Gut Liver. 2013;7(6):648–654.
      15. Zakharova, N.V., Simanenkov V. I., Savilova I. V., Svarval' A. V. Helicobacter pylori – izotopnaya diagnostiki infektsii i testirovanie rezistentnostiyu. Farmateka. 2016;2:24–27.
      16. Matysiak-Budnik T., Mégraud F. J. Epidemiology of Helicobacter pylori infection with special reference to professional risk. Physiol Pharmacol. 1997;48(Suppl 4):3–17.
      17. Hildebrand P., Meyer-Wyss B.M., Mossi S., Beglinger C. Risk among gastroenterologists of acquiring Helicobacter pylori infection: casecontrol study. BMJ. 2000;15:321–349.
      18. Birkenfeld S., Keter D., Dikman R. et al. Predominio de la infección de los píloros de Helicobacter en el personal del Salud-Cuidado de las clínicas primarias del cuidado y de la gastroenterología. Diario de la Gastroenterología Clínica. 2004;38:19–23.
      19. Nagy P., Johansson S., Molloy-Bland M. Systematic review of time trends in the prevalence of Helicobacter pyloriinfection in China and the USA. Gut Pathog. 2016;8:8. doi:10.1186/s13099-016-0091-7
      20. Xia P., Ma M. F., Wang W. Status of Helicobacter pylori infection among migrant workers in Shijiazhuang, China. Asian Pac J Cancer Prev. 2012;13(4):1167–1170.
      21. Shtygasheva O. V. Rasprostranennost' infektsii Helicobacter pylori i chastota dispepsicheskikh zhalob u naseleniya. Rossiiskii zhurnal gastroenterologiii, gepatologii, koloproktologii. 2004;1:33–36.
      22. Svarval' A.V., Ferman R. S., Zhebrun A. B. Izuchenie dinamiki prevalentnosti infektsii, obuslovlennoi Helicobacter pylori, sredi razlichnykh vozrastnykh grupp naseleniya Sankt-Peterburga v 2007–2011 godakh. Infektsiya i immunitet. 2012;2(4):741–746.
      23. Goto T., Haruma K., Kamata T. et al. Marked decrease of Helicobacter pylori infection in asymptomatic children in Japan. Gut. 1996;39(Suppl. 2):481.


    Full text is published :
    Bakulina N.V., Simanenkov V.I., Bakulin I.G., Ilchishina T.A. PREVALENCE OF HELICOBACTER PYLORI INFECTION AMONG PHYSICIANS . Experimental and Clinical Gastroenterology Journal.2017;148(12):20-24.
    Read & Download full text

    1. Moscow Scientific-Research Institute of epidemiology and microbiology (Moscow, Russian Federation)

    Keywords: probiotic and prebiotic products, prevention of dysbiosis, eradication therapy

    Abstract: The article shows the causal factors in the development of gastric ulcer, current approaches to the treatment and eradication treatment. The aim of the research was to study the clinical efficacy and tolerability of synbiotic «Normospectrum» in complex therapy of diseases of the stomach and duodenum. 44 people aged 17 to 53 years (the major group) received «Normospectrum». The control group consisted of 47 people of similar age who did not receive the drug. Analysis of clinical characteristics showed that patients receiving «Normospectrum», the improvement of health and the relief of symptoms of disorders of the gastrointestinal tract in the main group was 2–5 days earlier than patients in the control group, 65 % of patients. Positive clinical dynamics was confirmed in conducting a urease breath test. The test was performed at admission of patients and after the eradication therapy. Patients of the main group the positive effects of the ongoing eradication therapy on the background of the «Normospectrum» according to the urease breath test was 89 %, while patients in the control group to 71 %.

      1. Vasilenko V.Kh. Chego my ne znaem o yazvennoi bolezni (puti izucheniya problemy). Aktual'nye voprosy gastroenterologii. Moscow, 1970; vol. 1, pp.3-17.
      2. Warren J.R., Marshall B.J. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet, 1983;1:1311-1315.li>
      3. Isakov V.A., Domaradskii I.V. Khelikobakterioz. Moscow, 2003. 412 p.
      4. Baranskaya E.K. Yazvennaya bolezn' i infektsiya Helicobacter pylori. Russkii Meditsinskii Zhurnal. 2000; 1:8-14.
      5. Minushkin O.N., Aronova O.V. Sovremennyi vzglyad na problemu eradikatsii Helicobacter pylori. Praktikuyushchii vrach. 2002;1:52-54.
      6. Tsimmerman Ya.S., Vedernikov V.E., Novikov V.N., Kas'yanova N.L. Mikroflora slizistoi obolochki lukovitsy dvenadtsatiperstnoi kishki i ee rol' v patogeneze retsidiva yazvennoi bolezni. Sib. zhurn. gastroenterol., gepatol. 2001;12-13: 61-63.
      7. Ardatskaya M.D., Minushkin O.N., Ikonnikov N.S. Disbakterioz kishechnika: ponyatie, diagnosticheskie podkhody i puti korrektsii. Vozmozhnosti i preimushchestva biokhimicheskogo issledovaniya kala. Posobie dlya vrachei. Moscow, 2004.
      8. Bondarenko V.M., Gracheva N.M., Matsulevich T.V. Disbakteriozy kishechnika u vzroslykh. Moscow, 2003. 224 p./li>
      9. Korshunov V.M., Efimov B.A., Pikina A.P. Kharakteristika biologicheskikh preparatov i pishchevykh dobavok dlya funktsional'nogo pitaniya i korrektsii mikroflory kishechnika. Zhurn. mikrobiol. 2000; 3:86-91.
      10. Maev I.V., Samsonov A.A., Golubev N.N. Antibiotikoassotsiirovannaya diareya. Gastroenterologiya. 2007;1:45-49.
      11. Osipov G.A., Parfenov A.I., Verkhovtseva N.V., Ruchkina I.N., Kurchavovo V.A., Boiko N.B., Rogatina E.L. Klinicheskoe znachenie issledovaniya mikroorgani и zmov slizistoi obolochki kishechnika kul'tural'no–biokhimicheskim i khromato–mass–spektrometricheskim metodami. Eksperimental'naya i klinicheskaya gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2003; 4:59-67.
      12. Aleshkin A.V., Isaev R.R., Rubal'skii O.V., Amerkhanova A.M., Panov A.A. Sinbiotik Normospektrum v lechenii zabolevanii zheludka i dvenadtsatitiperstnoi kishki. Vestnik Rossiiskogo gosudarstvennogo meditsinskogo universiteta. 2009;2:19-22


    Full text is published :
    Volchetski A.L. INTESTINAL DYSBIOSIS AS A CONSEQUENCE OF ERADICATION THERAPY H. PYLORI AND A NEW APPROACH TO ITS CORRECTION.Experimental and Clinical Gastroenterology Journal . 2017;148(12):25-29
    Read & Download full text

    1. Kirov state medical university under the Ministry of Health of the Russian Federation (Kirov, Russian Federation)

    Keywords: coronary heart disease, gastroduodenal pathology, Нelicobacter pylori, morphological status, kristalloskopiya of saliva

    Abstract:Aim. The comparative analysis of the functional and morphological status of patients with coronary heart disease (CHD) with a combination of gastroduodenal pathology against the background of different options of treatment of gastroduodenal pathology (GDP). Subjiects and methods. In the course of the open prospective research features of a current of CHD in case of a combination to the GDP associated with Helicobacter pylori(n=147) in comparison with the patients of CHD who don’t have the GDP (n=147) were studied. For the purpose of studying of influence of different options of treatment of the GDP оn efficiency of treatment of sick CHD patients were divided into three groups. Patients of the I group received eradikatsionny + basic therapy, patients of the II group received antisekretorny + basic therapy. The III group was constituted by patients with the isolated CHD, receiving only therapy. Estimated dynamics of the morphological status and kristallogenny activity of saliva. Results. At sick CHD in case of a combination to the GDP the morphological pattern of the expressed inflammatory process, significant lowering of kristallogenny activity and violation of dehydrational structurization of saliva is revealed. After treatment (eradikatsionny + basis therapy) at 94,6 % of patients of the I group permanent endoscopic remission of a gastroduodenal zone, normalization of kristallogenny activity of the facies of saliva was marked. Conclusion. Inclusion of eradikatsionny therapy in an algorithm of treatment of sick CHD from the GDP associated with Helicobacter pylori along with achievement of kliniko-morphological remission of a gastroduodenal zone promotes increase in extent of restoration of dehydrational structurization of saliva in comparison with antisekretorny therapy.

      1. Alekseeva O.P., Pikulev D.V., Dolbin I.V. Ishemicheskaya bolezn' serdtsa i gastroezofageal'naya reflyuksnaya bolezn': sindrom vzaimnogo otyagoshcheniya (Klinicheskaya illyustratsiya). Klinicheskie perspektivy v gastroenterologii, gepatologii. 2012;3:31-34.
      2. Zvenigorodskaya L.A., Bondarenko E.Yu., Morozov I.A., Chikunova B.Z. Yazvennaya bolezn' u pozhilykh: klinicheskie osobennosti i znachenie H.pylori. Klinicheskaya gerontologiya. 2007;13(1):9-14.
      3. Pavlov O.N. Nositel'stvo Helicobacter pylori kak skrytyi sistemnyi faktor riska. Meditsinskii al'manakh. 2011;13(4):125-130.
      4. Kratnov A.E., Pavlov O.N. Infektsiya Helicobacter pylori i sostoyanie antioksidantnoi zashchity u patsientov s nestabil'nym techeniem ishemicheskoi bolezni serdtsa. Eksperimental'naya i klinicheskaya gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2004;5:4-9.
      5. Simonova Zh.G., Martusevich A.K. Otsenka effektivnosti eradikatsionnoi terapii u patsientov s sochetaniem yazvennoi bolezni zheludka i ishemicheskoi bolezni serdtsa. Vrach-aspirant. 2012;55(6):28-33.
      6. Martusevich A.K., Kolevatykh E.P. Kristalloskopicheskaya kartina biozhidkostei pri yazvennoi bolezni. Eksperimental'naya i klinicheskaya gastroenterologiya – 2006;6:35-40
      7. Martusevich A.K., Kamakin N.F., Simonova Zh.G. Molekulyarnye mekhanizmy strukturoobrazovaniya v vysykhayushchikh kaplyakh biologicheskikh substratov. Vyatskii meditsinskii vestnik. 2011;2:32-38.
      8. Maev I.V., Samsonov A.A., Golubev N.N., Kucheryavyi Yu.A., Belyavtseva E.V., Korovina T.I., Barkalova E.V. Khelikobakter-assotsiirovannaya forma yazvennoi bolezni zheludka i dvenadtsatiperstnoi kishki: problemy terapii. Farmateka – Pharmateca. 2011;215(2):10-17.
      9. Bakuev M.M., Saidov M.Z., Butakov A.A. Osobennosti sekretsii mieloperoksidazy i khemilyuminestsentnogo otveta neitrofilov cheloveka pri kontakte so stimulyatorami razlichnoi prirody. Immunologiya. 1991;1:15-17.
      10. Franceschi F., Niccoli G., Ferrante G., Gasbarrini A., Baldi A., Candelli M., Feroce F., Saulnier N., Conte M., Roccarina D., Lanza G.A., Gasbarrini G., Gentiloni S.N., Crea F. CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis. 2009;202(2):535-542.
      11. Stone A.F., Mendall M.A., Kaski J.C., Edger T.M., Risley P., Poloniecki J., Camm A.J., Northfield T.C. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA): STAMINA. Circulation. 2002;106(10):1219-1223.
      12. Pellicano R., Fagoonee S., Rizzetto M., Ponzetto A. Helicobacter pylori and coronary heart disease: which directions for future studies? Critical Reviews in Microbiology. 2003;29(4):351-359.
      13. Zhang S.et al. Cytotoxin-associated gene-A-seropositive virulent strains of Helicobacter pylori and atherosclerotic diseases: a systematic review. Chinese Medical Journal. 2008;121(10):946-951.


    Full text is published :
    Simonova Zh.G., Martusevich A.K. FEATURES OF THE FUNCTIONAL AND MORPHOLOGICAL STATUS OF PATIENTS WITH CORONARY HEART DISEASE AT A COMBINATION TO GASTRODUODENAL PATHOLOGY. Experimental and Clinical Gastroenterology Journal. 2017;148(12):30-36
    Read & Download full text

    1. FSEBI of HE «The Ulianov Chuvash State University» (Cheboksary, Russian Federation)
    2. SAI APE «Postgraduaute Medical Institute» of the Ministry of Health of the Chuvash Republic» (Cheboksary, Russian Federation)
    3. AI «Republican Clinical Oncology Centre» of the Ministry of Health of the Chuvash Republic (Cheboksary, Russian Federation)

    Keywords: irritable bowel syndrome, diagnostic criteria, extent of examinations, diff erential diagnostics

    Abstract: Introduction. Clinical signs of the irritable bowel syndrome (IBS) are not specific and can accompany other organic diseases. Following only the Rome criteria eligibility and the anxiety syndrome occurrence may result in diagnostic pitfalls and delayed diagnosis of grave diseases. In Russian gastroenterology IBS has always been and is still considered a diagnosis by exclusion. That is why IBS cannot by called a diagnosis found during the first visit to a physician. IBS is a diagnosis by exclusion that can be made only a patient’s systematic evaluation. Materials and methods. The article represents three clinical observations of patients with IBS. Diagnoses were made in full concordance with the Rome criteria. Nevertheless systematic evaluation according to the Clinical recommendations of the Russian Gastroenterological Association (RGA) revealed other diseases. Conclusions. Verification of the IBS diagnosis demands great responsibility on the side of a physician. To avoid diagnostic mistakes it is necessary to use all the examination procedures regulated in the Russian clinical recommendations.

      1. Ivashkin V.T., Shelygin Yu.A., Baranskaya E.K., Belousova E.A., Vasil'ev S.V., Golovenko O.V., Golovenko A.O., Grigor'ev E.G., Kostenko N.V., Kashnikov V.N., Kulikovskii V.F., Lapina T.L., Maev I.V., Poluektova E.A., Rumyantsev V.G., Timerbulatov V.M., Tikhonov A.A., Trukhmanov A.S., Fomenko O.Yu., Khalif I.L., Khubezov D.A., Chashkova E.Yu., Chibisov G.I., Sheptulin A.A., Shifrin O.S., Yanovoi V.V.Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii i Assotsiatsii koloproktologov Rossii po diagnostike i lecheniyu bol'nykh s sindromom razdrazhennogo kishechnika. Rossiiskii zhurnal gastroenterologii, gepatologii, kolonoproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;2:43-49.
      2. Ivashkin V.T., Shelygin Yu.A., Baranskaya E.K., Belousova E.A., Beniashvili A.G., Vasil'ev S.V., Golovenko A.O., Golovenko O.V., Grigor'ev E.G., Kostenko N.V., Lapina T.L., Loranskaya I.D., Lyashenko O.S., Maev I.V., Poluektova E.A., Rumyantsev V.G., Timerbulatov V.M., A.S. Trukhmanov A.S., Fomenko O.Yu., Khalif I.L., Chashkova E.Yu., Sheptulin A.A., Shifrin O.S., Yanovoi V.V.Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii i Assotsiatsii koloproktologov Rossii po diagnostikei lecheniyu sindroma razdrazhennogo kishechnika. Rossiiskii zhurnal gastroenterologii, gepatologii, kolonoproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017; 27(5):76-93.
      3. Andreev D.N., Zaborovskii A.V., Trukhmanov A.S., Maev I.A., Ivashkin V.T. Evolyutsiya predstavlenii o funktsional'nykh zabolevaniyakh zheludochno-kishechnogo trakta v svete Rimskikh kriteriev IV peresmotra (2016 g.). Rossiiskii zhurnal gastroenterologii, gepatologii, kolonoproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):4-11.
      4. Pimanov S.I. Silivonchik N.N. Rimskie IV rekomendatsii po diagnostike i lecheniyu funktsional'nykh gastroenterologicheskikh rasstroistv. Moscow, 2016. 160 p.
      5. Sheptulin A.A., Vize-Khripunova M.A. Sravnitel'naya otsenka amerikanskikh, nemetskikh, frantsuzskikh i rossiiskikh rekomendatsii povedeniyu bol'nykh s sindromom razdrazhennogo kishechnika. Rossiiskii zhurnal gastroenterologii, gepatologii, kolonoproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;2:92-101.
      6. Sheptulin A.A. Sindrom razdrazhennogo kishechnika: chto my vidim «vnutri khrustal'nogo shara»? Russkii meditsinskii zhurnal. Gastroenterologiya. – 2014;20:1437-1441.
      7. Butorova L.I., Tokmulina G.M. Sindrom razdrazhennogo kishechnika: osnovnye printsipy diagnostiki i lecheniya v poliklinicheskoi praktike. Moscow, Prima Print, 2014. 96 p.
      8. Tarasova L.V., Trukhan D.I. Bolezni kishechnika. Klinika, diagnostika i lechenie. Saint Petersburg, SpetsLit, 2013. 144 p.
      9. Loranskaya I.D., Lavrent'eva O.A. Sistemnyi podkhod k lecheniyu sindroma razdrazhennogo kishechnika. Russkii meditsinskii zhurnal. 2012;15:758-761.


    Full text is published :
    Tarasova L.V., Busalayeva E.I., Zhuchkova S.М. IS IT SO EASY TO DIAGNOSE IRRITABLE BOWEL SYNDROME? Experimental and Clinical Gastroenterology Journal. 2017;148(12):37–40
    Read & Download full text

    1. Voronezh State Medical University named after N. N. Burdenko (Voronezh, Russian Federation)

    Abstract: The purpose of this research was to study efficiency of Remaxol inclusion in complex therapy scheme for patients with chronic viral hepatitis C, genotype 3a. The analysis of treatment of 93 patients (43 men and 50 women) with verified diagnosis: medium-heavy form of chronic HCV, 3a genotype during replication phase (RNA HCV +) was performed. Patients’ average age was 42.8 ± 13.4 years, the duration of the disease was up to 5 years. Depending on the regimen of therapy patients were divided into two groups. 46 patients were included in main group. In addition to combined antiviral therapy (Pegintron and Ribavirin 24-week course) they received intravenously drip of Remaxol (400 ml 1 once a day during 12 days). Patients of the control group (n = 47) received only antiviral therapy. Clinical indicators dynamics were assessed (asthenic vegetative syndrome, hepatosplenomegaly, etc.) and, additionally, complexed laboratory studies were conducted: viral RNA detection with determination of the genotype, examination of antibody response levels, biochemical indicators (ALAT, AST, alkaline phosphatase, γ-glutamyl transpeptidase, total bilirubin) and cytokine profile (level of TNF-α, interleukins 2, 4 and 10). Medical test (liver biopsy by Mengini) was performed on 22 patients twice: not earlier than 6 months before the beginning of therapy and after the end of treatment. Our study revealed that remaxol therapy has a positive effect on clinical course of HCV serotype 3a by reducing severity of major clinical syndromes (asthenic vegetative syndrome and cholestatic syndrome). Twelve-day course of Remaxol helps to improve functional state of liver, improves membrane stabilizing and anti-cholestatic effects, which is confirmed by decrease in main biochemical indicators of hepatocellular damage — cytolysis and cholestasis. Inclusion of the drug in therapy in patients with chronical HCV, serotype 3a, increases cytoprotection and immunocorrection and, all in all, effectiveness of treatment.

      1. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiiskoi Federatsii v 2015 godu: Gosudarstvennyi doklad [On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2015: State report]. Moscow, Federal'naya sluzhba po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiya cheloveka. 2015. 115 p.
      2. Tselikovskii A.V., Pritulina Yu. G., Astapchenko D. S., Shentsova V. V., Krivoruchko I. V. Vliyanie steatoza pecheni na effektivnost' kombinirovannoi protivovirusnoi terapii khronicheskogo gepatita C [Influence of steatosis of the liver on the effectiveness of combined antiviral therapy of chronic hepatitis C.]. Sovremennye problemy nauki i obrazovaniya – Modern problems of science and education. 2012; 6: 186.
      3. Yan Z, Wang Y, Viral and host factors associated with outcomes of hepatitis C virus infection (Review). Molecular Medicine Reports. 2017; 15(5):2909–2924. doi: 10.3892/mmr.2017.6351.
      4. Gheonea D.I., Drocaş A.I., Mitroi G., Dobriţoiu M., Comănescu M.V., Stănculescu A.D., Cioboată R., Jieanu C.F., Tomescu P.I. The impact of liver steatosis on early and sustained treatment response in chronic hepatitis C patients. Romanian Journal Morphology and Embryology. 2017;58(1):107-113.
      5. Ivashkin V.T., Maevskaya M.V. Klinicheskie rekomendatsii po diagnostike i lecheniyu nealkogol'noi zhirovoi bolezni pecheni Rossiiskogo obshchestva po izucheniyu pecheni i Rossiiskoi gastroenterologicheskoi assotsiatsii [Clinical recommendations for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2016,2:24–42.
      6. Rekomendatsii po diagnostike i lecheniyu vzroslykh bol'nykh s gepatitom C [Recommendations for the diagnosis and treatment of adult patients with hepatitis C.] M., 2017, 69 p.
      7. Mato J. M., Martnez-Chantar M. L., Lu S. C. Methionine metabolism and liver disease. Annual Review of Nutrishion. 2008; 28: 273–93. doi: 10.1146/annurev.nutr.28.061807.155438
      8. Vlasov A.P., Bunyatyan N. D., Baranova O. N., Shibitov V. A., Vlasov P. A., Anaskin S. G. Patogeneticheskii podkhod k korrektsii enteral'noi nedostatochnosti [Pathogenetic approach to correction enteral insufficiency]. Klinicheskaya farmakologiya i terapiya. 2012;21(2):79–82.
      9. Mitsura V.M., Zhavoronok S. V., Krasavtsev E. L., Pav-lovich I. L., Suetnov O. N., Grushko T. P. Soderzhanie tsitokinov v syvorotke krovi bol'nykh khronicheskim gepatitom S pri interferonoterapii i kombinirovannoi terapii al'fa-interferonom i Ronkoleikinom Immunologiya, allergologiya, infektologiya. [The content of cytokines in the blood serum of patients with chronic hepatitis C with interferon therapy and combined therapy with alpha interferon and Roncoleukin]. Immunologiya, allergologiya, infektologiya. 2003;2:98–101.


    Full text is published :
    Pritulina Yu.G., Salomakhin G.G., Fil G.V. EFFECTIVENESS OF USE OF REMAXOL HEMATOPHYLENE PROTECTOR IN COMPLEX THERAPY OF CHRONIC HEPATITIS C.Experimental and Clinical Gastroenterology Journal. 2017;148(12):41-46
    Read & Download full text